PROTOKOLwiki
COMPOUNDS / NOOTROPIC / PRAMIRACETAM
NOOTROPIC

PRAMIRACETAM

LOW RISK
BEST FOR:Cognition●●●●●●●○○○7/10
PRAMIRACETAM · CI-879 · PRAMISTAR · NEUPRAMIR · PRAMIRACETAM SULFATE
NootropicRacetamCholinergicCognitive EnhancerLipophilic

A fat-soluble racetam nootropic that enhances choline uptake and acetylcholine synthesis in the hippocampus.

ROUTE / DOSAGE
LOW250mg
STANDARD500-800mg
HIGH1200mg+
Note: Take with a choline source to reduce headache risk; inverted U-shaped dose-response means higher doses may be less effective
CYCLE
Daily use acceptable for up to 2-4 weeks cycling not established but periodic breaks recommended
BIOAVAILABILITY
~50% oral
ACTIVE DURATION
8-12h (subjective)
STORAGE
Room temperature dry away from light
HALF-LIFE
4.5-6.5 h (plasma)
DURATION BREAKDOWN
Total8-12 hours
Onset30-90 min
Come up1-2h
Peak2-4 hours
Offset3-5 hours
After effects2-4 hours
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
6 documented
Enhanced memory consolidation and recall
Improved focus and concentration
Increased cholinergic neurotransmission
Faster information processing speed
Neuroprotective effects under hypoxic conditions
Mild alertness without stimulation
§ 02 — RISKS
Headache from choline depletion when taken without a choline source
Gastrointestinal discomfort including nausea
Insomnia or sleep disturbance if taken late in the day
Inverted U-shaped dose-response curve means higher doses may be less effective
Limited long-term human safety data
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

Clinical trials demonstrate that pramiracetam partially reversed scopolamine-induced amnesia in healthy volunteers across age groups. A placebo-controlled study in head injury patients showed clinically significant improvements in delayed recall and memory measures, maintained over an 18-month open-trial period. Animal studies found enhanced reference memory in radial maze tasks at 7.5 and 15 mg/kg doses. However, a trial in Alzheimer's disease patients found doses up to 4,000 mg unlikely to confer symptomatic benefit, with an inverted U-shaped dose-response curve. Pharmacokinetic data show linear dose-proportional plasma concentrations with peak at 2-3 hours and elimination half-life of 4.5-6.5 hours. Evidence for cognitive enhancement in healthy non-impaired individuals remains limited and largely anecdotal.

§ 06 — SOURCES
[1]
Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers
pubmed.ncbi.nlm.nih.gov ↗
[2]
The action of pramiracetam on consequences of hypobaric hypoxia is only moderate
pubmed.ncbi.nlm.nih.gov ↗
[3]
Pharmacokinetics of oral pramiracetam in normal volunteers
pubmed.ncbi.nlm.nih.gov ↗
[4]
The effect of pramiracetam (CI-879) on the acquisition of a radial arm maze task
pubmed.ncbi.nlm.nih.gov ↗
[5]
Pharmacokinetics of pramiracetam in animals
pubmed.ncbi.nlm.nih.gov ↗
[6]
Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia
pubmed.ncbi.nlm.nih.gov ↗
[7]
Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam
pubmed.ncbi.nlm.nih.gov ↗
[8]
Pharmacokinetics of pramiracetam in healthy volunteers after oral administration
pubmed.ncbi.nlm.nih.gov ↗
[9]
PsychonautWiki - Pramiracetam
psychonautwiki.org ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT